COMPANY IS HEADING TOWARD A $20MM SERIES “A” RAISE
Sarasota, Florida 05/010/2021 — Omeza, LLC announced today that it has closed on the sale of $5,000,000 of convertible notes to 22 current and 6 new investors. The notes carry a 15% discount, 6% accrued interest and a $40,000,000 valuation cap. This puts the company 25% of the way toward its $20,000,000 Series “A” capital raise. The capital being raised is being used to finance commercial operations for the Omeza® collagen matrix wound treatment kit, which generates more equitable access and better outcomes for patients, improves workflows and profits for all sites of care, and lowers total cost of care for payers.
Company founder and CEO Tom Gardner stated, “Our Pre-market Notification application is under substantive review with FDA, and we are raising capital to support the launch of our patent-protected Omeza® collagen matrix Rx drug-device combination product.”
With the closing of the sale of convertible notes, total investment in Omeza now totals $13,000,000, all of it from individuals. The Series “A” round likely will be the company’s first institutional round.
Omeza is being advised on Series “A” by Westbury Group.
This announcement is for informational purposes only.